Compare DFIN & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFIN | KROS |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 655.9M |
| IPO Year | N/A | 2020 |
| Metric | DFIN | KROS |
|---|---|---|
| Price | $46.27 | $20.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $63.50 | $22.20 |
| AVG Volume (30 Days) | 272.4K | ★ 969.1K |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.12 | ★ 1.57 |
| Revenue | ★ $750,800,000.00 | $246,718,000.00 |
| Revenue This Year | N/A | $6,876.34 |
| Revenue Next Year | $4.20 | N/A |
| P/E Ratio | $40.84 | ★ $13.23 |
| Revenue Growth | N/A | ★ 37798.31 |
| 52 Week Low | $37.80 | $9.12 |
| 52 Week High | $69.93 | $22.55 |
| Indicator | DFIN | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 47.77 | 57.16 |
| Support Level | $44.10 | $20.73 |
| Resistance Level | $46.60 | $21.75 |
| Average True Range (ATR) | 1.37 | 1.06 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 41.10 | 57.76 |
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.